MYC and neoplasm: Nuclear β-catenin IHC status at diagnosis was known in 58/72 patients (14 % positive, 8/58 tumours assessed) and CTNNB1 mutation status in 55 (5 % mutated, 3/55), MYC/MYCN status in 33/72 patients (9 % MYCN amplified, 3/33, no MYC amplified), and chromosome 17 imbalances/diploid background in 32/72 patients (ch17(im)/diploid(cen); 31 %, 10/32) [6].